1. Armand J, Fontana X, DeForni M, Carde P, Munck N, Cvitkovic E, Malet Martino MC (1987) A phase I study of DuP 785 (NSC 368 390) using a 5 daily IV schedule. Proc Am Soc Clin Oncol 6: 46
2. Arteaga C, Brown T, Kuhn J, Shen H, O'Rourke T, Beougher K, Brentzel H, Von Hoff D, Weiss G (1989) Phase I clinical and pharmacokinetic trial of brequinar sodium (DuP 785, NSC 368 390). Cancer Res 49: 4648?4653
3. Bork E, Vest S, Hansen H (1989) A phase I clinical and pharmacokinetic study of brequinar sodium, DuP 785 (NSC 368 390), using a weekly and a bi-weekly schedule. Eur J Clin Oncol 25: 1403?1411
4. Chen S, Ruben R, Dexter D (1986) Mechanism of action of the novel anticancer agent 6-fluoro-2-(2?-fluoro-1, 1?-biphenyl-4-yl)-3-methyl-4-quinoline carboxylic acid sodium salt (NSC 368 390): inhibition of de novo pyrimidine nucleotide biosynthesis. Cancer Res 46: 5014?5019
5. Currie V, O'Hehir M, Baltzer L, Slavik W, Yaldaei S, Bertino J (1988) Phase I trial of DuP 785 given on a single weekly intravenous dosing schedule. Proc Am Soc Clin Oncol 7: 76